Hetero Labs Limited Indomethacin Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Indomethacin Export Records India — #1 Exporter, 144 Shipments, $3.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Indomethacin

India Pharmaceutical Trade Intelligence

$9.4M139 Suppliers70 CountriesHS 30049099

ExportsIndia → UNITED STATES68.0%India → CANADA4.3%

ImportsUNITED STATES → India$205.8K CANADA → India$68.6K

#1 Supplier: HETERO LABS #1 Buyer: GLENMARK PHARMACEUTICALS

Hetero Labs Limited — Indomethacin Exporter #1 | $3.9M Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Indomethacin Exporter Profile

Indian Pharmaceutical Exporter · #1 for Indomethacin · $3.9M export value · DGFT Verified

Hetero Labs Limited is the #1 Indian exporter of Indomethacin with $3.9M in export value and 144 verified shipments. Hetero Labs Limited holds a 41.6% market share in Indomethacin exports across 3 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Indomethacin Export Profile: Buyers & Destinations

Hetero Labs Limited Indomethacin export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Indomethacin?

Country	Value	Shipments	Share
UNITED STATES	$2.8M	110	74.9%
CANADA	$405.8K	18	11.0%
UNITED STATES OF AMERICA	$320.2K	9	8.7%
CHILE	$204.0K	7	5.5%

Who Are the Top Buyers of Indomethacin from Hetero Labs Limited?

Buyer	Country	Value	Orders
TO THE ORDER OF	UNITED STATES	$2.0M	78
TO THE ORDER OF....	UNITED STATES	$985.2K	38
M S TO THE ORDER OF MINT PHARMACEUTICALS	CANADA	$161.2K	4
MINT PHARMACEUTICALS INC.	CANADA	$132.4K	6
M/S.	UNITED STATES	$100.0K	2
SEVEN PHARMA CHILE SPA	CHILE	$100.0K	2
TO THE ORDER	UNITED STATES	$99.5K	2
TO THE ORDER OF---	CANADA	$66.0K	2
TO THE ORDER OF`,	CANADA	$46.2K	6
CAMBER PHARMACEUTICALS INC	UNITED STATES	$39.5K	3

Hetero Labs Limited supplies Indomethacin to 11 buyers globally. The largest buyer is TO THE ORDER OF (UNITED STATES), followed by TO THE ORDER OF.... (UNITED STATES) and M S TO THE ORDER OF MINT PHARMACEUTICALS (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Indomethacin Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
INDOMETHACIN CAPSULE	$865.3K	36
INDOMETHACIN CAPS	$339.9K	10
INDOMETHACIN CAPSULENOS	$290.5K	24
INDOMETHACIN 25MG CAPSULE	$240.3K	9
INDOMETHACIN 50MG CAPSULE	$221.5K	5
INDOMETHACIN 75MG CAPS (7848x100's PACK)	$129.7K	4
INDOMETHACIN CAPSULE 100`S	$107.7K	3
INDOMETHACINA INDOMETHACIN 25MG CAPSULE30S	$100.0K	2
INDOMETHACIN 50MG CAPS (19344x100's PACK	$94.5K	2
INDOMETHACIN 50MG CAPS (19536x100's PACK	$94.3K	2

Hetero Labs Limited exports 38 distinct Indomethacin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is INDOMETHACIN CAPSULE with 36 shipments worth $865.3K.

How Does Hetero Labs Limited Compare to Nearest Indomethacin Exporters?

Exporters ranked immediately above and below #1 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	HETERO LABS LIMITED ★	$3.9M	144	3	$27.1K
2	GLENMARK PHARMACEUTICALS LIMITED	$1.6M	112	4	$14.1K
3	ZYDUS LIFESCIENCES LIMITED	$650.0K	13	2	$50.0K

Hetero Labs Limited ranks #1 among 139 Indian Indomethacin exporters. Average shipment value of $27.1K compared to the market average of $60.6K. The closest competitors by value are GLENMARK PHARMACEUTICALS LIMITED and ZYDUS LIFESCIENCES LIMITED.

Which Indian Ports Ship Indomethacin Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	173	13.9%
SAHAR AIR	164	13.1%
SAHAR AIR CARGO ACC (INBOM4)	157	12.6%
DELHI AIR	113	9.1%
NHAVA SHEVA SEA (INNSA1)	92	7.4%
HYDERABAD ICD	66	5.3%
JNPT	53	4.2%
Bombay Air	48	3.8%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Indomethacin Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Indomethacin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 144 individual customs records matching Hetero Labs Limited exporting Indomethacin, covering 38 formulations to 4 countries via 11 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 70+ countries, 242+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Indomethacin

Indomethacin

Hetero Labs Limited — Indomethacin Exporter Profile

Hetero Labs Limited — Indomethacin Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Indomethacin?

Who Are the Top Buyers of Indomethacin from Hetero Labs Limited?

What Is India's Total Indomethacin Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Indomethacin Exports?

How Does Hetero Labs Limited Compare to Other Indian Indomethacin Exporters?

What Indomethacin Formulations Does Hetero Labs Limited Export?

Regulatory Requirements: Exporting Indomethacin to Key Markets

United States — FDA

Canada — HC

How Does Hetero Labs Limited Compare to Nearest Indomethacin Exporters?

Which Indian Ports Ship Indomethacin Exports?

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Indomethacin Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Indomethacin Export Data from Hetero Labs Limited

Indomethacin Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source